Catheter-Directed Bivalirudin for Local Anticoagulation and Clot Dissolution in Children Requiring Mechanical Circulatory Support
Chaudhry-Waterman N, Schardt TQ, Soderstrom RM, Warren BB, Buckvold S, Morgan G, Kim JS (2025) · ASAIO Journal · n=3
Perfil del estudio
- Diseño
- case series of three pediatric mechanical circulatory support patients receiving catheter-directed bivalirudin for localized thrombolysis (Children's Hospital Colorado)
- Tamaño de la muestra (n)
- 3
- Intervención
- Direct bivalirudin delivery via catheter to localized intracardiac/circuit thrombosis in MCS patients
- Comparador
- Historical alteplase-based catheter-directed thrombolysis
- Punto final primario
- Thrombus resolution and bleeding complications after catheter-directed bivalirudin
- Resultado primario
- Direct bivalirudin delivery associated with rapid thrombus resolution in all three cases; novel application combining anticoagulant prevention with active fibrin-bound thrombin clearance
- Duración del seguimiento
- Acute MCS course
- PMID
- 40960390
Hallazgos clave
- Case series of catheter-directed bivalirudin thrombolysis in pediatric mechanical circulatory support
- All three cases achieved rapid thrombus resolution
- Used in patients with alteplase contraindications (bleeding history)
- Leverages bivalirudin's fibrin-bound thrombin inhibition
- Novel application warranting larger series
Limitaciones
- Only 3 cases - hypothesis-generating only
- Single-center experience
- No control comparison
- Dosing not standardized for catheter-directed application
- Not applicable to whole-leech hirudotherapy
Implicaciones clínicas
Chaudhry-Waterman 2025 introduces novel catheter-directed bivalirudin use for localized thrombolysis in pediatric MCS patients. For ASH, this case series demonstrates the ongoing innovation cycle in the synthetic hirudin-derivative pharmaceutical pathway - new applications discovered through reasoning about mechanism (fibrin-bound thrombin inhibition). The K040187 device-leech US clinical practice operates under a more stable indication landscape without analogous novel-use innovation.
Estudios relacionados
Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial
Fuchs J, Cannon CP (1995)
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW (2009)
Experience with pharmacologic leeching with bivalirudin for adjunct treatment of venous congestion of head and neck reconstructive flaps
Harun A, Kruer RM, Lee A, Boahene K, Byrne PJ, Richmon JD (2018)
Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article
Wang G, Qi K, Li X, Zuo S, Zhang R, Zhao Y, Sun S, Zhang J, Liu X (2024)